Full-Time
Confirmed live in the last 24 hours
EEG devices for monitoring brain activity
$115k - $250kAnnually
Senior
Kansas City, MO, USA
You match the following Ceribell's candidate preferences
Employers are more likely to interview you if you match these preferences:
Ceribell focuses on developing medical devices that utilize electroencephalogram (EEG) technology to monitor brain activity. Their main product, the Ceribell EEG Headband and Recorder, is designed for use by trained healthcare providers in professional settings. These devices help gather important data about a patient's brain activity, which healthcare professionals can analyze to make informed treatment decisions. Unlike some other EEG devices, Ceribell's products do not provide diagnostic conclusions or automated alerts; they are purely tools for data collection. This is particularly important in urgent medical situations, such as Nonconvulsive Status Epilepticus (NCSE), where quick access to brain activity data can significantly impact patient outcomes. Ceribell generates revenue by selling these EEG devices to healthcare providers, adhering to regulations that require a physician's order for their use.
Company Size
201-500
Company Stage
Series C
Total Funding
$146.9M
Headquarters
Mountain View, California
Founded
2014
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Unlimited Paid Time Off
Paid Holidays
Parental Leave
Annual Bonus Opportunity
Company Equity
Phone/Internet Stipend
—Ms. Rodenbush to lead hiring and talent development initiatives— —Mr. Price to focus on market development and penetration— SUNNYVALE, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions (“Ceribell”), today announced the appointments of Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing to its leadership team. “Ms
Ceribell, a former Fierce Medtech Fierce 15 honoree, has been developing a point-of-care electroencephalography platform that combines a disposable, brain-reading headset with artificial intelligence-powered algorithms that help detect hidden seizures-also known as electrographic status epilepticus, or ESE.
CeriBell, a medical device maker with an EEG platform that uses AI to monitor patient seizures, announced terms for its IPO on Monday.
Healthcare sales veteran to lead sales strategies and initiatives to propel continued commercial growthSUNNYVALE, Calif., April 2, 2024 /PRNewswire/ -- Today, Ceribell, Inc.®, the developer of the first AI-powered point-of-care EEG diagnostic system, announced the appointment of Sean Manni as Senior Vice President of Sales. In this role, Mr. Manni will lead Ceribell's commercial sales organization as it continues to expand its U.S. footprint."Sean brings an impressive blend of accomplishments, strategy, and leadership that will undoubtedly elevate our entire commercial organization," said Ceribell co-founder and CEO Jane Chao, Ph.D. "His guidance will be instrumental in developing and executing our plans to further expand our market presence in the U.S., ultimately benefiting patients by increasing access to our groundbreaking technology.""Joining Ceribell represents a unique opportunity to collaborate with an exceptional leadership and sales team," said Manni. "I am deeply committed to leveraging my experience in healthcare sales to further innovate Ceribell's sales strategies and ensure our revolutionary AI-powered point-of-care EEG solutions reach patients in need."Mr
SUNNYVALE, Calif., Jan. 4, 2024 /PRNewswire/ -- Ceribell, Inc.®, the developer of the first AI-powered point-of-care EEG system, announced today that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 8, 2024, at 8:00 a.m. Pacific Standard Time.Event: 42nd Annual J.P. Morgan Healthcare ConferenceDate: Monday, January 8, 2024Time: 8:00 a.m